Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial
Key Takeaways
- Retatrutide is an investigational once-weekly injection developed by Eli Lilly. It is not FDA-approved as of May 2026 and is only legally available through enrollment in a TRIUMPH phase 3 trial.
- It is a triple-hormone-receptor agonist that activates GIP, GLP-1, and glucagon receptors in one molecule, distinguishing it from semaglutide (GLP-1 only) and tirzepatide (GIP plus GLP-1).
- In the phase 2 trial (Jastreboff et al., NEJM June 2023), 12 mg weekly produced a mean weight loss of about 24.2% at 48 weeks in adults with obesity, the largest figure recorded in any obesity pharmacotherapy trial to date.
- The TRIUMPH phase 3 program is studying retatrutide across obesity, type 2 diabetes, obstructive sleep apnea, and knee osteoarthritis. First regulatory submissions are not expected before 2026-2027.
- FormBlends does not sell, supply, or formulate retatrutide. This page is educational.
Direct answer
Retatrutide is an experimental obesity and diabetes drug being developed by Eli Lilly. It is a single molecule that activates three different gut and pancreatic hormone receptors (GIP, GLP-1, and glucagon), making it the first "triple agonist" in late-stage clinical development. It is not FDA-approved as of May 2026, has not received regulatory approval in any country, and is currently being studied in phase 3 trials under the TRIUMPH program. The phase 2 trial reported the largest mean weight loss ever recorded in an obesity drug study, around 24% of body weight at the highest dose.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The plain-language definition
- Where retatrutide came from
- What "triple agonist" means in practical terms
- What the phase 2 trial actually showed
- Where the phase 3 program stands
- How retatrutide is different from semaglutide and tirzepatide
- What is unknown about retatrutide
- Why "research peptide" retatrutide is not the same thing
- The contrary view: should anyone be excited about a 24% figure?
- Who should care about retatrutide today
- FAQ
- Sources
The plain-language definition
Retatrutide is a once-weekly injection that is being tested as a treatment for obesity and, separately, for type 2 diabetes, obstructive sleep apnea, and knee osteoarthritis. It belongs to the same family of drugs as Ozempic and Mounjaro (the incretin family), but it works on three receptors at once instead of one or two.
It is not on the market. You cannot buy it from a pharmacy. It is not FDA-approved. The only legal way for a U.S. patient to receive retatrutide right now is by enrolling in one of Lilly's active phase 3 trials and being randomized to the active-drug arm.
FormBlends does not sell, supply, formulate, or prescribe retatrutide. This article exists because the search volume for "what is retatrutide" is rising fast and people deserve accurate information instead of marketing copy from gray-market peptide vendors.
Where retatrutide came from
Retatrutide is the third major incretin program from Eli Lilly. The timeline:
| Year | Lilly milestone |
|---|---|
| 2005 | Exenatide (Byetta) approved, first GLP-1 receptor agonist on the U.S. market (originally Amylin, later acquired) |
| 2014 | Dulaglutide (Trulicity) approved for type 2 diabetes, weekly GLP-1 |
| 2022 | Tirzepatide (Mounjaro) approved for type 2 diabetes; dual GIP/GLP-1 agonist |
| 2022 | First retatrutide phase 1 data presented (development code LY3437943) |
| 2023 | Tirzepatide (Zepbound) approved for chronic weight management |
| 2023 | Phase 2 retatrutide trial published in NEJM (Jastreboff et al., June 2023) |
| 2023-2026 | TRIUMPH phase 3 trials enrolling across obesity, T2D, OSA, and knee OA |
The lineage matters. Retatrutide was not built from scratch. It is the next step in Lilly's effort to layer additional gut-hormone signaling onto a GLP-1 backbone. Tirzepatide added GIP. Retatrutide adds glucagon on top of that.
What "triple agonist" means in practical terms
The body uses several hormones to manage hunger, blood sugar, and energy expenditure. Three of them are relevant here.
GLP-1 (glucagon-like peptide-1): Released by the gut after eating. Slows gastric emptying, increases satiety, and stimulates insulin in a glucose-dependent way. This is the receptor that semaglutide, dulaglutide, and liraglutide target.
GIP (glucose-dependent insulinotropic polypeptide): Also released by the gut after eating. Enhances insulin secretion and appears to modulate fat storage. This is the second receptor that tirzepatide targets.
Glucagon: Released by the pancreas during fasting. Increases hepatic glucose output and, more interestingly for obesity, increases energy expenditure and lipolysis (fat breakdown).
Retatrutide activates all three. The clinical thesis is that combining appetite suppression (GLP-1) and metabolic enhancement (GIP) with increased energy burn and fat oxidation (glucagon) produces larger weight loss than any single mechanism could.
The phase 2 data appears to support that thesis, with one notable wrinkle. The glucagon arm of the molecule is the most distinctive piece. Activating glucagon receptors typically raises blood sugar, which is the opposite of what you want for a diabetes drug. Lilly's design balances the glucagon effect with strong GIP and GLP-1 insulin secretion, so net glucose effects in trials have been favorable. That balance is part of what makes retatrutide a difficult engineering problem.
What the phase 2 trial actually showed
The phase 2 trial (Jastreboff AM et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial," published in the New England Journal of Medicine in June 2023) enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Participants were randomized to placebo or one of several retatrutide doses (1 mg, 4 mg, 8 mg, or 12 mg) once weekly for 48 weeks.
| Dose arm | Mean weight loss at 48 weeks |
|---|---|
| Placebo | ~2.1% |
| Retatrutide 1 mg | ~8.7% |
| Retatrutide 4 mg | ~17.1% |
| Retatrutide 8 mg | ~22.8% |
| Retatrutide 12 mg | ~24.2% |
The 24.2% figure at the highest dose is what generated the headlines. For context, the SURMOUNT-1 tirzepatide trial (Jastreboff et al., NEJM 2022) reported a mean of about 22.5% at the highest dose (15 mg weekly), and the STEP 1 semaglutide trial (Wilding et al., NEJM 2021) reported about 14.9% at 2.4 mg weekly.
Important caveats from the phase 2 trial:
- The 48-week weight curve had not plateaued in any arm. Participants were still losing weight when the trial ended. The "true" maximum weight loss with longer treatment is unknown.
- Most common adverse events were gastrointestinal: nausea, diarrhea, vomiting, constipation. These were dose-dependent and most pronounced during titration.
- Heart rate increased modestly in retatrutide arms (about 6 beats per minute on average at the highest dose), a finding not seen to the same degree with semaglutide.
- No new safety signals emerged that prevented progression to phase 3.
Where the phase 3 program stands
Lilly's phase 3 program is called TRIUMPH. As of May 2026, the public-facing trial registry shows:
- TRIUMPH-1: Retatrutide in adults with obesity. Estimated primary completion around late 2026.
- TRIUMPH-2: Retatrutide in adults with obesity and type 2 diabetes.
- TRIUMPH-3: Retatrutide for cardiovascular outcomes in patients with overweight or obesity. Long-term follow-up; results not expected until later in the decade.
- TRIUMPH-4: Retatrutide for obstructive sleep apnea.
- Additional trials: Knee osteoarthritis, hepatic steatosis, and pediatric obesity programs are at various stages.
Best-case FDA submission timing for an obesity indication is late 2026 to 2027, with approval potentially in 2027-2028. That assumes no major safety signals and a clean review. The tirzepatide timeline is the closest comparison: SURPASS phase 3 trials reported out in 2021, FDA approval for diabetes followed in May 2022, and approval for obesity (Zepbound) in November 2023.
How retatrutide is different from semaglutide and tirzepatide
| Feature | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro/Zepbound) | Retatrutide (investigational) |
|---|---|---|---|
| Receptors targeted | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + Glucagon |
| Manufacturer | Novo Nordisk | Eli Lilly | Eli Lilly |
| FDA approval status | Approved (2017 diabetes, 2021 obesity) | Approved (2022 diabetes, 2023 obesity) | Not approved, investigational |
| Dosing | Weekly subcutaneous | Weekly subcutaneous | Weekly subcutaneous (in trials) |
| Mean weight loss (pivotal trial) | ~14.9% at 2.4 mg (STEP 1) | ~22.5% at 15 mg (SURMOUNT-1) | ~24.2% at 12 mg (phase 2 only) |
| Liver fat reduction signal | Modest | Strong | Strongest of the three in early data |
| Heart rate effect | Mild increase | Mild increase | More pronounced increase (~6 bpm at 12 mg) |
| Long-term outcomes data | Robust (SELECT, STEP extension) | Growing (SURMOUNT-4, SURPASS-CVOT) | Not yet available |
The shorthand: semaglutide has the longest track record. Tirzepatide has the best balance of efficacy and known safety. Retatrutide has the largest weight-loss signal so far, but it is the least studied and the safety database is the smallest.
What is unknown about retatrutide
Anyone selling certainty about retatrutide is selling something else. The honest list of what we do not yet know:
- Long-term safety beyond 48 weeks. The phase 2 trial stopped at 48 weeks. Phase 3 data will extend that, but multi-year real-world safety profiles do not exist.
- Cardiovascular outcomes. The heart rate increase is a flag that requires careful study. TRIUMPH-3 is the dedicated cardiovascular outcomes trial; results are years away.
- Comparative effectiveness vs. tirzepatide. No head-to-head trial has been published. Cross-trial comparisons (24% vs 22.5%) are not the same thing as a randomized comparison.
- Weight-loss maintenance. Retatrutide has not been studied in withdrawal or maintenance designs equivalent to STEP 4 or SURMOUNT-4.
- Effects in non-obese populations. All retatrutide trials enrolled patients with obesity or overweight with comorbidities. Use in normal-weight patients is not characterized.
- Pricing and access strategy. Lilly has not signaled pricing. Insurance coverage policy will emerge after approval.
- Drug-drug interactions. Standard interaction profiles will be characterized during phase 3.
Why "research peptide" retatrutide is not the same thing
This section is here because the question is unavoidable and the answer matters for safety.
Web searches for "retatrutide" surface vendors selling vials marketed as retatrutide "for research use only." These products are not the same as the retatrutide being studied in TRIUMPH trials. Specifically:
- They are manufactured outside the FDA-regulated pharmaceutical supply chain. Identity, purity, sterility, and potency are not verified by any U.S. regulatory body.
- Independent testing of research peptide vendors has repeatedly shown variability in actual peptide content, presence of contaminants, and inaccurate labeling. (See Marfella et al. 2024 and Tucker et al. 2023 in Journal of the American Pharmacists Association.)
- Selling these products for human use is unlawful. Importing them, possessing them, or self-administering them carries legal risk and significant medical risk.
FormBlends's position is unchanged: we do not supply, source, formulate, or recommend research-grade retatrutide. This article describes the regulated medication in clinical trials, not the gray-market product sold online. If you are considering self-administering a research peptide, the more useful conversation is with a clinician about why, and what FDA-approved alternatives exist (semaglutide, tirzepatide, liraglutide).
The contrary view: should anyone be excited about a 24% figure?
Pharma analysts and obesity researchers have been measured rather than ecstatic about retatrutide. The reasons are worth taking seriously.
The trial was 48 weeks, not 72. SURMOUNT-1 ran 72 weeks. STEP 1 ran 68 weeks. The retatrutide curve had not plateaued at 48 weeks, but neither has it been tested across an equivalent duration. Direct comparisons to tirzepatide are time-mismatched.
Phase 2 numbers often shrink in phase 3. Larger, more diverse phase 3 populations typically produce somewhat smaller effect sizes than tightly controlled phase 2 populations. Lilly's own tirzepatide trajectory is the example: phase 2 tirzepatide data was strong, and SURMOUNT-1 confirmed it, but the magnitude was slightly smaller in the larger trial.
The heart rate signal needs more study. A 6-bpm average increase at the highest dose is not catastrophic, but it is larger than the increase typically seen with semaglutide. Cardiovascular safety has been the historical Achilles heel of weight-loss drugs (fen-phen, sibutramine, rimonabant). Retatrutide's signal is not in the same category as those failed drugs, but it warrants careful monitoring.
The 24% is an average, not a guarantee. Individual response varied widely in the trial. Some participants lost less than 10%; others lost more than 30%. Patients reading "24% weight loss" often hear "I will lose 24%." That is not how trial averages work.
Approval is not certainty. Multiple promising obesity drugs failed at the phase 3 or post-approval stage (lorcaserin, naltrexone-bupropion underperformed expectations). Retatrutide is more promising than most, but "phase 3 ongoing" is not the same as "approved."
Who should care about retatrutide today
If you are currently on semaglutide or tirzepatide and progressing toward your goal:
- Continue your current therapy. Switching to a hypothetical future drug is not relevant to your present decisions.
- Retatrutide will not be available for 1-3 years even in the best case, and insurance coverage will lag approval.
If you have plateaued on semaglutide and are considering tirzepatide:
- Tirzepatide is the appropriate next step. Retatrutide is not yet an option.
- The cross-trial data suggests modest additional benefit from retatrutide over tirzepatide, but the comparison is not robust.
If you are a clinician:
- Track the TRIUMPH program for safety and effectiveness data.
- Be prepared to counsel patients away from research peptide vendors while educating them about the legitimate retatrutide development timeline.
If you are simply curious:
- The honest answer is "promising, but not yet proven, and not yet available."
- The most useful next reading is the phase 2 NEJM paper itself, which is open access on the journal's site.
FAQ
What is retatrutide? Retatrutide is an investigational triple-hormone-receptor agonist developed by Eli Lilly. It activates GIP, GLP-1, and glucagon receptors in a single molecule. It is not FDA-approved as of May 2026 and is currently in phase 3 trials.
Is retatrutide approved by the FDA? No. Retatrutide has not received FDA approval. It is being studied in the TRIUMPH phase 3 program. Earliest possible approval is 2027-2028 based on typical regulatory timelines.
Can I buy retatrutide? Not legally for human use. Vials sold online as "research peptide" retatrutide are not the same product being studied by Lilly, are not regulated, and are not safe to use as medication. Enrolling in an active TRIUMPH trial is the only legal U.S. route.
How much weight loss did retatrutide produce in trials? The phase 2 trial showed a mean of about 24.2% body weight loss at 48 weeks with 12 mg weekly. Phase 3 results have not been published.
What is the difference between retatrutide and tirzepatide? Tirzepatide targets two receptors (GIP and GLP-1). Retatrutide targets three (GIP, GLP-1, and glucagon). Tirzepatide is FDA-approved. Retatrutide is not. Cross-trial weight loss appears slightly larger for retatrutide, but the two have not been compared head-to-head.
Who makes retatrutide? Eli Lilly and Company. The development code is LY3437943.
How is retatrutide given? Once-weekly subcutaneous injection in clinical trials. Commercial format would likely match other Lilly incretins.
When will retatrutide be available? Earliest FDA approval is plausible in 2027-2028 if phase 3 trials report cleanly. Real-world availability typically lags approval by 6-12 months.
What are the side effects? Phase 2 reported nausea, diarrhea, vomiting, constipation, and modest heart rate increase. Dose-dependent and most pronounced during titration. Long-term side effects are not yet characterized.
Is retatrutide better than Wegovy? Cross-trial weight loss is larger with retatrutide (24% vs ~15% for Wegovy). But Wegovy is FDA-approved, has long-term safety data, and is commercially available. Retatrutide is not yet a usable comparison.
Does retatrutide work for diabetes? Phase 2 data showed favorable effects on glucose control. The TRIUMPH-2 phase 3 trial is dedicated to type 2 diabetes outcomes. Final efficacy and safety in diabetes are pending.
What does retatrutide do to the liver? Phase 2 results showed reduced hepatic fat content. The mechanism appears related to the glucagon receptor activation, which increases lipolysis and fat oxidation. Dedicated liver-disease trials are ongoing.
Sources
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. June 2023.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022.
- Rosenstock J et al. Retatrutide Once Weekly in Type 2 Diabetes: Phase 2 Trial. Lancet. 2023.
- Eli Lilly and Company. TRIUMPH Phase 3 Clinical Trial Program Overview. ClinicalTrials.gov registry, accessed May 2026.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
- Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
- Tucker AS et al. Quality Analysis of Compounded and Research-Grade GLP-1 Receptor Agonists Marketed Online. Journal of the American Pharmacists Association. 2023.
- FDA Drug Approvals Database. Tirzepatide and Semaglutide approval records, accessed May 2026.
- American Association of Clinical Endocrinologists. Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. 2024 update.
- Endocrine Society. Clinical Guidance on Investigational Incretin Therapies. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital telehealth platform that connects patients with independent licensed clinicians and U.S. state-licensed pharmacies. We do not manufacture, prescribe, or dispense medication directly. FormBlends does not sell, supply, or formulate retatrutide.
Compounded Medication Notice. Compounded semaglutide and compounded tirzepatide offered through FormBlends are prepared by 503A state-licensed compounding pharmacies in response to individual prescriptions. Compounded drugs are not FDA-approved and have not undergone the same review as brand-name products. Retatrutide is not available as a compounded medication through FormBlends and is investigational under federal law.
Results Disclaimer. Phase 2 retatrutide weight-loss figures are trial averages, not personal guarantees. Individual response varied widely in the published data. Any future outcomes from approved use would depend on baseline weight, adherence, comorbidities, and individual physiology.
Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Retatrutide is the international nonproprietary name for an investigational Eli Lilly compound and has no current brand name in the United States. FormBlends is not affiliated with Eli Lilly, Novo Nordisk, or any sponsor of the TRIUMPH clinical trial program.